US Eylea Biosimilar Approvals Set Up Competition On Aflibercept
Both Biocon And Biogen Receive Interchangeability Designations For Ophthalmic Treatment
Biocon and Biogen have received simultaneous US approvals for aflibercept biosimilar rivals to Eylea, with both products also receiving interchangeability designations. However, launches may have to wait while IP issues are resolved.
